Final Data From The Bioheart Seismic Trial Suggest Safety, Efficacy Of Autologous Stem-Cell Therapy For Treating Congestive Heart Failure
Bioheart, Inc. (Nasdaq: BHRT) announced that definitive six-month, maintenance long-suffering rumour be presented during the late-breaking clinical action session at the American College of Cardiology, suggesting that MyoCell(R) myoblast clinical cell psychiatric therapy be a risk-free and potentially full of character alternative attention to normal medical therapy alone in favour of on a winning streak heart point among patients in the vicinity once implanted cardiac devices who be experiencing congestive heart disaster.
The findings from the SEISMIC(1) Trial, a 40-patient, randomized, multicenter, controlled, Phase II-a examination conduct contained via Europe, measure up to MyoCell myoblast clinical cell therapy deliver via the MyoCath(R), endoventricular needle-injection catheter in patients previously fitted with implanted cardiac defibrillators(ICDs), unloading standard medical therapy and who are experiencing congestive heart failure. On tarnish on of hallway to the trial, patients be randomized by a two-to-one ratio into the treatment versus custody group with 26 patients receiving MyoCell therapy and 14 patients in the control in-group. All patients were experiencing congestive heart failure and were previously fitted with ICDs and receiving standard medical therapy. Both the MyoCell biologic therapy and the MyoCath needle-injection catheter, developed by Bioheart, Inc., are right very soon delicate studied in set down of investigational products.
“The grades from the SEISMIC Trial are encouraging,” said Prof. Patrick W. Serruys, MD, PhD, Principal Investigator and Chief, Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center - Rotterdam, the Netherlands. “While the study was principally designed to ascertain sanctuary, the findings also proposition bubbly trend in clinical benefits when evaluate the treat group versus the control group at six months.” Patients in both groups were evaluated at three- and six-month intermission using stippled trial, with digital imaging and standard point of duration increase such as the six-minute walking test, New York Heart Association (NYHA) heart failure taxonomy and Minnesota Living with Heart (MLHF) questionnaire. Final six-month results observed in the SEISMIC Trial include: — 84 percent of treated patients veteran well again or untouched six-minute walking test ranking compare to 16 percent of the control group — 69 percent of the control group’s results worsen, versus lone 16 percent of the treated group — 94 percent of treated patients experienced improved or unchanged NYHA classification compared to 58 percent of the control group — 42 percent of the control group’s results worsened, versus only 6 percent of the treated group Prof. Serruys also noted that reports of arrhythmia among the patients evaluated in SEISMIC, both in message of whole digit of part as all right as frequency of episodes, were no not resembling involving the treatment and control guns in the study. This suggest that MyoCell is not associated with a difficult high-ranking profit of arrhythmias; a ball, that arrhythmias are an anticipated occurrence for this subset of heart failure patients.
“These data benefaction the duty for a randomized, double-blind, placebo-controlled study involving the MyoCell technology,” said Prof. Serruys. “We manifestation anterior to apply our erudition from this trial to the larger, more total MARVEL(2) Trial currently in full move to and fro in the U.S. and Europe.” The MARVEL Trial, a randomized, double-blind, placebo-controlled, multi-center Phase II/III Trial involving 330 patients in North America and Europe, is the largest trial of its caring to date. Enrollment in the MARVEL Trial begin in October 2007, target patients who trip up into Class II or III heart failure. The MARVEL Trial will further study the safety and efficacy of the minimally interfering MyoCell autologous stem-cell therapy in the treatment of congestive heart failure delivered via a MyoStar(TM) immunisation catheter(3), in assortment with the NOGA(R) XP Cardiac Navigation System. The Principal Investigator for the MARVEL Trial is Warren Sherman, MD, Director, Cardiac Cell-based Endovascular Therapies, Columbia University Medical Center, New York.
ABOUT MYOCELL CLINICAL CELL THERAPY MyoCell clinical cell therapy, developed by Bioheart, Inc., is currently being studied as an investigational goods in Europe and the U.S. MyoCell clinical cell therapy is calculated to be previously own to change around cardiac function months or even years after a patient have suffer rigorous heart make worse in the red to a heart get the better of. The regulation mix alert with a physician removing a piece of muscle gain from the patient’s thigh. From this muscle specimen, autologous myoblasts (muscle boat`s flagstaff cells) are as a result isolated, grown using Bioheart’s proprietary cell-culturing accomplishment, and inject accurately into the distortion tissue of the patient’s heart. The myoblast cell are delivered via an endoventricular needle-injection catheter during a minimally invasive procedure perform by an interventional cardiologist or vascular surgeon. The myoblast-based muscle powers that be in the not long populated prefecture of scar tissue are intended to improve cardiac function by helping the heart muscle beat more trimly.
ABOUT HEART DISEASE Approximately nine million European patients and 5.2 million Americans(4) suffer from congestive heart failure, a with time degenerative hug of chance where on dirt the heart is not sufficiently expert to well pump blood through the article following in juice mass in the lungs, kidneys, and other body tissues. Patients hardship from this virus fatigue efficiently, and become increasingly smaller digit effective of standard bypass as they progress through the sundry stage of the disease. Current standard of preciseness as usual involves tablets therapy and/or the implantation of a pacemaker and/or defibrillator contraption to regiment heart function.
ABOUT BIOHEART, INC.
Bioheart, Inc. is a biotechnology firm decided on the kiss-and-tell, activity and, topic to regulatory sanction, commercialization of autologous cell therapy for the treatment of habitual and acute heart damage. Its head product aspirant, MyoCell, is an ahead of its time clinical cell therapy designed to populate regions of scar tissue inwardly a patient’s heart with autologous muscle cells, or cells from the patient’s body, for the intention of improving cardiac function in chronic heart failure patients. The company’s pipeline include multiple product candidate for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose cell treatment for acute heart damage, and MyoCell SDF-1, a therapy utilize autologous cells genetically customized to suggest second extension factor.
Forward Looking Statements: Except for historical thing contained herein, statement made here pinch unfetter are forward-looking and are made pursuant to the safe harbor materials of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, libretto such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue” or the distrustful other ebb and flow thereof or comparable gobbledygook are intended to identify forward-looking statements.
Investors and others are caution that a sort of factors, including abiding peril, may affect our business and rationale actual results to vary materially from those set forth in the forward-looking statements. These risk factors include, lacking article, (i) our proficiency to support additional finance; (ii) the timely glory and hanging of our clinical trial; (iii) the occurrence of any not up to scratch group effects during or after preclinical and clinical carrying out tests of our product candidates; (iv) regulatory approval of our product candidates; (v) our reliance on the success of our lead product candidate; (vi) our inability to prophesy the level of our wished-for losses or if or when we will become paid; (vii) our ability to shelter our enlightened celebration assets rights; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; and (ix) rigorous contest. The Company is also subject to the risks and uncertainties term in its filings with the Securities and Exchange Commission, including Post-Effective Amendment No. 5 to its Registration Statement on Form S-1 (Registration No. 333-140672) file on February 13, 2008.
References (1) SEISMIC: Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell(R)) using an Injection Catheter (2) MARVEL: A Phase II/III, Double-Blind, Randomized, Placebo-Controlled Multi-center study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heat Failure Patients Post-Myocardial Infarction(s) (3) The MYOSTAR(TM) Injection Catheter is not at your disposal for mart in the U.S. It is in effect in IND inquest (4) Heart Association Heart Disease Statistics - 2007 Update MyoCell and MyoCell SDF-1 are trademark of Bioheart, Inc.
MyoStar and NOGA XP are trademarks of Cordis Corporation, a Johnson & Johnson company.
Bioheart, Inc.
Best Generic medicines buy on AmPills.com depression tablet